BioSpace News Archive

It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look.

Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary algal cultures, today announced the closing of the sale of an additional 150,000 shares of common stock,

BioSig Technologies, Inc. announced pricing of its previously announced underwritten public offering of 2,500,000 shares of its common stock, $0.001 par value per share, at a price to the public of $4.00 per share.

The Pharmaceutical Industry Labor-Management Association today released an update to its first-of-its-kind report on the economic impact of the long-standing partnership between skilled craft unions and the biopharmaceutical industry in Illinois and 13 other states.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced three oral presentations and nine poster presentations related to valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress being held July 17-21, 2021

Breckenridge Pharmaceutical, Inc. announces that it has signed a multi-product agreement with Welding GmbH & Co. under which Welding will develop, manufacture and supply pharmaceutical products for marketing, sale and distribution by Breckenridge.

Parexel, a leading global clinical research organization focused on development and delivery of innovative new therapies to advance patient health, announced the execution of a definitive merger agreement under which it will be acquired by EQT IX fund and the Private Equity business within Goldman Sachs Asset Management from Pamplona Capital Management LP for $8.5 billion.

The EQT IX fund and the Private Equity business within Goldman Sachs Asset Management have agreed to acquire Parexel, a leading global clinical research organization from Pamplona Capital Management for an enterprise value of USD 8.5 billion.

LMC Pathology Services (LMC), a Sonic Healthcare USA Anatomic Pathology Practice, is the first reference laboratory in the United States to offer the VENTANA MMR RxDx Panel from Roche Diagnostics for evaluation of endometrial cancer, approved by the FDA on April 22, 2021.

CEL-SCI Corporation announced that the discussion at the Annual Shareholder Meeting, on July 1, 2021 at 10:00 am EDT, regarding its Phase 3 head and neck cancer trial results is available at https://edge.media-server.com/mmc/p/ou79u5bv.